You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Screening the Ribosome for New Target Sites

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Aminopiperidines as novel anti influenza agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Influenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government